Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

Quidel Corporation

With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year. Quidel is the nation’s leading developer of the only rapid point-of-care diagnostic Lyme disease test. In recent years the company launched the critically acclaimed and award-winning LymeDiseaseAnswers.com website and Lyme Quick Takes online video series. “The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years they have helped fund the most urgent and promising research in the field while expanding education and awareness programs for the public and physicians. We’re honored to have this collaborative partnership.” As part of its collaboration, Quidel will serve as sponsor for GLA’s Lyme awareness month as well as a series of educational PACE-accredited webinars. These events provide new information on various Lyme topics in an open discussion format, all designed to bring awareness around the Lyme disease epidemic, with rapid ways to diagnose and treat it. In addition, Quidel will be a sponsor for the GLA Global Gala 2022, the organization’s premier fundraising event to be held in October. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’ s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’ s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities, and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

June 09, 2022 06:00 AM Pacific Daylight Time

Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference

1BusinessWorld

Sylvester Feddes, the Country President and Pharma Head of Novartis Colombia, joins the 2022 Leading Entrepreneurs of the World Conference to talk about leading diversity and inclusion in a virtual environment. At Novartis Colombia, Sylvester and his team use innovative science and technology to address some of society's most challenging healthcare issues by discovering and developing breakthrough treatments and finding new ways to deliver them to as many people as possible. The LEW Conference is one of the largest and most comprehensive entrepreneurial events in the world and features business presentations, digital interviews, discussions and roundtables with the world's leading entrepreneurs and business leaders. Register to attend the 2022 LEW Conference to watch the live session of Sylvester's presentation and to connect with him live at the event: https://events.zoom.us/e/view/_LwgIoXQQL2gA_LMBaozZA All news and content distribution in partnership with News Direct. About Novartis Novartis is a leading healthcare company providing solutions to the changing needs of patients. We use science-based innovation to address society's biggest health care challenges. We discover and develop advanced treatments and find new ways to ensure access to as many people as possible. Likewise, we seek to guarantee an effective return for those who invest time, resources and ideas in our company. Our goal is to improve global health. Through our business, we make an important contribution to society: we discover and develop innovative medicines. Novartis works hand in hand with others to help address some of the world's biggest health challenges. Novartis About Leading Entrepreneurs of the World As part of 1BusinessWorld, Leading Entrepreneurs of the World is one of the largest and most comprehensive entrepreneurial platforms and events in the world and features entrepreneurs, founders and business leaders presenting on cutting-edge topics and the latest industry developments. Leading Entrepreneurs of the World About 1BusinessWorld 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details 1BusinessWorld Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

June 08, 2022 06:17 PM Eastern Daylight Time

Image

Oakland Pharmacy Inc. Partners With Comcast Business to Improve Network Management, Security and Speeds

Comcast California

Comcast Business today announced that it is providing Oakland Pharmacy Inc. – a business of community pharmacies and clinic pharmacies in Oakland, California region – with SD-WAN on the ActiveCore SM SDN Platform, Ethernet Dedicated Internet (EDI) connections for its sites as well as Business VoiceEdge® services and a 4G LTE backup connection. The combination of solutions is helping the local healthcare business improve operating procedures for its employees from the pharmacy counter to the IT desk – ultimately helping to provide elevated services for its customers. For more than 35 years, Oakland Pharmacy Inc. has served residents in Alameda County, working diligently to improve the healthcare opportunities within its communities, in particular for underserved populations – like the Asian Pacific Islander community, children incarcerated in the Juvenile Justice system, people experiencing homelessness and mental health patients – who need special healthcare assistance. Staff across the company’s seven locations are often bilingual, speaking Spanish, Cantonese, Vietnamese or Mandarin to better connect with the different cultural backgrounds that the locations serve. As medical records continue to shift to the cloud, it has become increasingly important for the pharmacy industry to have fast, reliable and secure network connections capable of quickly pulling and sending patient information. “I am very happy with the quality of service we’ve received,” said Timothy Tam, IT specialist for Oakland Pharmacy Inc. “Now our employees can more rapidly adjudicate claims, e-fax and process new prescriptions without worrying about slow network speeds.” In addition to the fast and reliable EDI connections, SD-WAN on the ActiveCore SM SDN Platform helps to configure the business’ network, as well as proactively monitor for, and troubleshoot, connectivity issues across Oakland Pharmacy Inc.’s various locations. Meanwhile, the company’s 4G LTE backup connection is helping to build network redundancy while its Business VoiceEdge® solution is providing great call quality plus a web portal to help manage calls and voicemails. “Our local pharmacies are truly the bastions of our communities. They keep us healthy, whether it’s providing vaccines, medications or other consultation on healthcare best practices,” said Kristeen Cominiello, vice president of Comcast Business in California. “Comcast Business recognizes that connectivity is the key to ensuring that these services continue to reach community members in need, and is proud to offer its support to Oakland Pharmacy Inc.” About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company that connects people to moments that matter. We are principally focused on connectivity, aggregation, and streaming with 57 million customer relationships across the United States and Europe. We deliver broadband, wireless, and video through our Xfinity, Comcast Business, and Sky brands; create, distribute, and stream leading entertainment, sports, and news through Universal Filmed Entertainment Group, Universal Studio Group, Sky Studios, the NBC and Telemundo broadcast networks, multiple cable networks, Peacock, NBCUniversal News Group, NBC Sports, Sky News, and Sky Sports; and provide memorable experiences at Universal Parks and Resorts in the United States and Asia. Visit www.comcastcorporation.com for more information. Contact Details Adriana Arvizo +1 925-200-1919 Adriana_Arvizo@comcast.com

June 08, 2022 09:05 AM Pacific Daylight Time

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells

Kadimastem

If the feasibility study is successful, it would be a significant step forward towards pancreatic tissue engineering that could be used to develop Kadimastem’s IsletRx for diabetes in a way where transplantation would be possible without concern of immune rejection Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring other neurodegenerative diseases and developing a potential cure for diabetes, has signed an agreement with Implant Therapeutics, Inc. for use of “Immune Evasive Cell” iACT cells, (Which are implant cells that the immune system does not recognize as foreign to the body) Implant's breakthrough technology to prevent transplant rejection. Under the terms of the agreement, a feasibility study will be conducted to test if Implant Therapeutic’s iACT TM cells can provide a solution to the challenge of transplant immune protection and avoidance of rejection of Kadimastem’s IsletRx for diabetes. If so, Implant Therapeutics iACT TM cells could be a good cell source for Kadimastem to create its glucose sensing, insulin producing pancreatic cells, the basis for IsletRx, without the need of Immune protection or immunosuppression. The iACT TM “Immune Evasive” cell technology uses genetic modifications to cloak cells to be seen as part of the receiving body’s immune system and therefore are not rejected following transplantation. The success of the licensing feasibility study would be a significant step forward towards the potential to create pancreatic islet organoids, capable of producing insulin and glucagon as well as regulating blood glucose levels, that would not be rejected by the body. A successful evaluation may result in the licensing by Kadimastem of Implant Therapeutics’ technology. Kadimastem CEO Asaf Shiloni said, “This strategic agreement with Implant is the result of a long-term effort we have invested in bringing the innovative “Immune Evasive” cell technology to Kadimastem. The new capability takes us to the forefront of the race to develop diabetes care and will allow us to apply advanced technologies to create an optimal and ultimate solution to the central problem of protecting cells from the patient's own immune system. I welcome the move and hope that this technology will further advance the development of IsletRx, with the ultimate goal of improving the lives of the millions of people living with diabetes worldwide." About IsletRx IsletRx is a cell therapy treatment for diabetes, achieved by expanding the population of allogeneic stem cells differentiated into functioning insulin and glucagon producing and releasing pancreatic islet cells. The company then uses a proprietary technology to select the highest functioning cells, enrich them and then transplant them into the body. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021, where the diabetes treatment program was discussed, and the company received directions how to prepare its Pre-IND submission. About Implant Therapeutics Implant Therapeutics is a subsidiary of panCELLa whose mission is to develop therapeutic products in the immunology and cell therapy space and to partner with other companies to develop novel products in areas of regenerative medicine. Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering human iPSC cells that incorporate failsafe, iACT, hypoimmunogenic and safe-harbor technologies. These iPSC cells are “Immune Evasive” and are an ideal choice for replacement strategies of many cell types combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. To learn more, visit www.implant-rx.com. About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

June 08, 2022 07:00 AM Eastern Daylight Time

Image

Telos Blockchain Sponsors Unbound Now Gala

Telos Foundation

The Telos Foundation is proud to announce that it will be the official sponsor for the 2022 Unbound Now Gala happening on June 7th in Waco, Texas. Telos is firmly in favor of all that Unbound Now stands for and has accomplished as a non-profit organization and is pleased to support them as they continue to provide aid for humanity’s most vulnerable. Tuesday’s gala celebrates 10 years of Unbound Now’s work to end human trafficking in local communities and around the world. Telos believes that global ESG concerns such as human trafficking, an illicit practice that has more than tripled in the last decade, must be eradicated at all costs. Unbound Now is leading the effort to help save the victims from this heartless act. Founded in the United States in 2012, Unbound Now has grown substantially, launching in several locations worldwide, including Cambodia, Mongolia, Indonesia, South Africa, and various countries in Europe. While their operations vary from one city to the next, Unbound offers three main lines of effort: Prevention and Awareness: Unbound Now works to educate and empower youth, spread awareness through citywide outreaches and provide human-trafficking presentations to groups and organizations. Professional Training: Unbound Now provides training to equip all professionals to use their skills to identify and serve victims of human trafficking. Survivor Advocacy: Unbound Now advocates for victims and survivors by meeting immediate needs, supporting survivors and their families, and connecting each survivor with resources for his or her unique restoration journey. The values and principles of the Telos team are closely aligned with those of Unbound Now and looks forward to making its contribution to put an end to human trafficking - once and for all. About Telos Live since 2018, Telos Blockchain (ticker: TLOS) is an ESG compliant Layer 1 smart contract platform that offers full-service compatibility with Solidity, Vyper and Native C++ smart contracts. The chain along with all of its departments operates at Net Zero status and offers the use of its fair smart contract powered governance system to any interested organization in modular fashion. The chain is capable of finalizing over a billion low-fixed-cost (w/ a feeless option) transactions per day. Since the launch of mainnet, Telos has operated with a flawless network uptime record. The validators of the network are globally decentralized, vetted (KYC) and are all equitable in size. Telos is one of the only Layer 1 Blockchain to be both credibly neutral in both its finances and its architecture. About The Foundation The Telos Foundation is a Decentralized Autonomous Organization established as a promotional and funding body to advance the Telos Blockchain Network and provide support to network applications. Contact Details The Team hello@telosfoundation.io Company Website https://www.telos.net/

June 07, 2022 10:21 AM Eastern Daylight Time

Video

Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference

Vascudyne, Inc.

Vascudyne, Inc., a biotechnology trailblazer in regenerative medicine, announced today that the first clinical results of TRUE AVC™ acellular vascular conduit in hemodialysis access will be presented at the Vascular Access Society of the Americas (VASA) conference in Charleston, South Carolina at 11:20 am EDT on June 10, 2022. The presentation, titled “First in Human Evaluation of a Novel Biologic Regenerative Vascular Conduit for Hemodialysis Access”, will be made by Vascudyne’s medical advisor Monnie Wasse, MD, MPH, FASN, Professor of Medicine in the Division of Nephrology and Department of Internal Medicine at Rush University Medical Center. Dr. Wasse serves as Vice-Chairperson for Clinical Operations for the Department of Medicine and is also the Director of Interventional Nephrology, focused on the planning and maintenance of dialysis vascular access for patients with kidney diseases. Dr. Wasse will present 6-month results and preliminary evidence of the safety and effectiveness of the device as a conduit for hemodialysis vascular access. Vascudyne’s TRUE™ Tissue products are unique, 100% biological, and become the patient’s own living and functional tissue. Nothing synthetic or artificial is ever used in the manufacturing process, in contrast to other regenerative medicine cardiovascular devices with synthetic polymer-based scaffolds that slowly degrade in the body and may lead to adverse immune response. “Dr. Wasse brings extensive experience and clinical expertise to our medical advisory board, and we are excited she is presenting the promising initial results from the TRUE AVC studies,” said Mark Stenoien, Vascudyne’s Chief Regulatory and Clinical Science Officer. Vascudyne announced in February its relocation to a high capacity GMP manufacturing facility to support TRUE AVC manufacturing through commercialization. “We are excited to share our first clinical results with our TRUE Tissue technology in hemodialysis access and have been working on developing our platform technology to address additional cardiovascular diseases” said Dr. Zeeshan Syedain, Vascudyne’s Chief Scientific Officer. “Our move to the new facility dramatically increased our GMP manufacturing space and added a dedicated cleanroom that is poised to support our ongoing TRUE AVC clinical studies all the way to commercialization,” added Dr. Syedain. TRUE AVC is not available for commercial sale. Dr. Monnie Wasse, MD, MPH, FASN Vascudyne’s Clinical Collaborators at Sanatorio Italiano in Asuncion, Paraguay Vascudyne’s TRUE AVC TM for Hemodialysis Access About Vascudyne Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a mission to improve patient care with regenerative biomaterials that are inspired by nature. Vascudyne, a privately held company founded in 2014, uses the TRUE™ Tissue technology to develop TRUE to Nature™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/. About TRUE Tissue Technology TRUE™ Tissue is developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be readily shaped into tubes, sheets, and other geometries making it suitable for many soft tissue applications, is mechanically comparable to native tissues, and is a ready to use, off-the-shelf allograft. Forward Looking Statements This announcement contains forward-looking statements. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements relate to future events or Vascudyne’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Vascudyne’s actual results, performance or achievements to be materially different. Vascudyne undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. Contact Details Sandy Williams, Marketing Director swilliams@vascudyne.com

June 07, 2022 09:23 AM Eastern Daylight Time

Image

ThreatModeler Announces New Patent for IaC-Assist

ThreatModeler Software, Inc

ThreatModeler, a leader in securing cloud infrastructure from design to deployment, today announced the issuance of their newest patent, which makes the IaC-Assist a proprietary technology. The patent, US Patent No. 20220004645A1, has been issued and granted as of April 26, 2022. With IaC-Assist, any user can truly shift left as it relates to implementing security within the code. Users can identify, review, and mitigate security flaws while writing the code in real-time - with simply the click of a button and without leaving their coding environment. IaC-Assist creates a more time and cost-efficient solution to the build process, saving developers the hours it would have taken to build designs and review its security. “Our patented solution, IaC-Assist, reduces threat drift from code to cloud and gives users a simple and efficient solution in truly shifting left,” said Archie Agarwal, Founder and CEO, ThreatModeler. “This patented technology is the only solution in the industry that helps you build threat models from your IDE itself and updates the threat model as you update the code. We’re excited to have these streamlined capabilities patented and available to users.” This patented technology solution is the first of its kind that helps to reduce threats from code to cloud. Users can implement the technology as a processor-executed method of generating a threat model from a code file. The system can analyze the code file, identify properties associated with the resources included in the code file, and generate a threat model based on the resources determined as a security threat. This technology addresses industry pain points by giving tools for security teams to work more collaboratively with the development organizations. Additionally, instead of adding more steps to the build and deploy process, this technology fits within the existing process and enables developers to build security within the code with the least amount of time lost. To learn more about this new patent and ThreatModeler technology, please visit here. About ThreatModeler Software, Inc. ThreatModeler Software, Inc. 's suite of products empowers DevOps to measure their threat drift from code to cloud. With a fraction of the time and cost tied to other tools, users can design, build and validate threat drift from development to deployment. Teams can instantly visualize their attack surface, understand security requirements and prioritize steps to mitigate threats. CISOs can make critical security-driven business decisions to scale their infrastructure for growth. Contact Details Clayton Murtle ThreatModeler@luminapr.com

June 07, 2022 08:00 AM Eastern Daylight Time

Freight Rate Transparency gains traction in Freight Forwarding – SHIFEX by Shifl

Shifl

Digital forwarding and supply chain platform Shifl has announced the launch of SHIFEX, an Ocean Spot Freight Rate Index for container shipments which is now available on their website ( https://shifl.com/index ). The recent and continuing unprecedented chaos in the freight markets has brought the dire need for transparency and visibility into actual ocean freight rates. Shabsie Levy, CEO and Founder of Shifl, said he often found thousands of dollars of disparities between reported and actual freight rates on the market. “In the current market condition, just about no one can afford to pay hundreds and sometimes thousands of dollars more for moving a single container,” said Levy. SHIFEX provides live insights into ocean freight rates. It tracks and displays the average ocean spot freight rates for 40'containers (FEU) on main Transpacific routes at any given period. Freight rate transparency and accuracy have always been touted as core business values. They improve customer engagement, build trust, and increase productivity in an industry that has been opaque. “By leveraging our existing technology, we are helping shippers benchmark the freight rates they should be paying for their shipments and help them better plan their order placements and inventory” said Levy. By analyzing its own data of actual bookings and shipments, Shifl was able to alert the market in advance of the drastic changes in the ocean spot freight rates across the volatile periods in 2021 and 2022. Eli Gelbman of The New York Doll Collection a company that manufacturers and sells childrens dolls and accessories says, "I am pleased that Shifl is launching SHIFEX. As a regular importer, we have been following Shifl's rate data in their market reports which has helped us tremendously in managing the volatility in the freight market. Having the same info now on-demand, will allow us to make better supply chain decisions, and improve efficiency in costing and in planning our orders." More about SHIFEX SHIFEX, the first ocean spot freight rate index by a US freight forwarder, provides live insights into ocean spot freight rates as it tracks and displays rates that are applicable on the Trans-Pacific route. SHIFEX is based on the actual spot freight rates quoted and/or paid for moving shipments on the Trans-Pacific route and is therefore a true reflection of the prevailing market conditions in the freight forwarding spot market. SHIFEX is offered as a free service by Shifl and covers Port to Port container spot freight rates. SHIFEX includes all commonly applicable surcharges, —including but not limited to BAF (Bunker and/or Emergency Bunker Adjustment Factor), CAF (Currency Adjustment Factor) ISPS (International Security Port Surcharge), PCS (Port congestion surcharge). The index provides past and current freight rates with the option of tracking rates on a 3, 5, 12 and 18 month basis from the base ports of China to both Los Angeles and New York. In addition to freight rates, Shifl is also planning to include its highly popular vessel transit and container dwell data and add spot freight rates of other trade lanes to SHIFEX so customers can track the past and current performance of these metrics as well. SHIFEX complements digital offerings that include Shifl.com, the digital forwarding and supply chain platform, and Shifl.capital, the cutting-edge FinTech solution designed to make business transactions easier for supply chain companies. About Shifl Shifl is leading the supply chain industry into the future with technology and innovation that brings a huge array of real-life benefits to its users. If you are a shipper looking to bring your business into today's digital age, be more in control, and pay less overall - Shifl is for you. Shifl is headquartered in New York and maintains a presence in China, India, Vietnam, Malaysia, Bangladesh, Georgia, DR, and The Philippines. To learn more, visit https://shifl.com. Contact Details CHARLIE PESTI Priyanka Ann Saini +91 98332 68264 priyanka@pesti.io

June 06, 2022 12:00 AM Eastern Daylight Time

CMEs Available at Integrative Health & Medicine Conference in October 2022

Academy of Integrative Health and Medicine

The 2022 Academy of Integrative Health & Medicine (AIHM) annual “ People. Planet. Purpose. Conference ” has been accredited by the University of California, Irvine, School of Medicine for continuing medical education (CME) credits. The conference, themed “Disruptive Innovation + the Future of Health,” will be held Oct. 28-30 in San Diego. Participation is available for in-person and virtual attendance options. Attendees can earn up to 54.25 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME credit breakdown as follows: Thursday, Oct. 27, pre-conference seminar, “Update on Hormone Therapy in Integrative Practice” – 3.75 Thursday, Oct. 27, pre-conference seminar, “Introduction to Psychedelic Assisted Psychotherapy: Clinical Use + Emerging Research” – 3.75 Friday, Oct. 28, general session – 6.5 Saturday, Oct. 29, general session – 5.75 Sunday, Oct. 30, general session – 4.5 On-demand virtual presentations – 30 People. Planet. Purpose. features experts, innovators, and visionaries in integrative health and medicine from across the globe talking about the latest research-based integrative techniques and strategies. Presenters include Deepak Chopra, MD; Sara Gottfried, MD; Shamini Jain, PhD; Scott Shannon, MD, ABIHM; Mimi Guarneri, MD; and Romie Mushtaq, MD, among others. More information and registration is available at aihm.org/conference. Early-bird pricing ends August 15. “Each year our presenters share ground-breaking developments and advances in truly integrative approaches to health, wellness and medicine,” said AIHM Executive Director Tabatha Parker, ND. “The AIHM conference allows physicians and other clinicians from a wide range of specialties to expand their understanding of whole-person care.” CME Information This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and the Academy of Integrative Health & Medicine. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, www.meded.uci.edu/cme, for AB 1195 and AB 241 resources. Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary and integrative health practitioners worldwide. In 2001, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research and advocacy. For more information, visit aihm.org or follow @aihmglobal on Facebook, Instagram, and Twitter. Contact Details Carol Stevenson +1 661-713-6879 carol@growthledge.com Company Website https://aihm.org

June 03, 2022 04:36 PM Eastern Daylight Time

1 ... 215 216 217 218 219 ... 301